Congestive heart failure and obstructive sleep apnea
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Zand, M.D.[2] Edzel Lorraine Co, D.M.D., M.D. [3]
Overview
Overview
Obstructive sleep apnea is a sleep-related breathing disorder with effects on cardiovascular system by increasing the risk of hypertension, coronary artery disease, cardiac arrhythmias, sudden cardiac death, and heart failure. Obstructive sleep apnea contributes to the development and progression of HF. Hypoxia caused activation of inflammatory pathway leading to endothelial damage, atherogenesis, and heart failure. Activate profibrotic transforming growth factor-β during inflammatory process may cause increased deposition of extracellular matrix and consequent myocardial fibrosis and worsening LV diastolic function.
Sleep apnea in heart failure disease
Sleep apnea in heart failure disease
- Sleep apnea is defined as partial or complete cessation of breathing during night-time sleep, resulting in repeated arousal from sleep, oxyhemoglobin desaturation, and daytime sleepiness.
- Apnea is as complete cessation of airflow for >10 s.
- Hypopnea, or partial cessation of airflow, is defined as a 50% to 90% reduction in airflow for >10 s, and >3% decrease in oxyhemoglobin saturation (SaO2) terminated by arousal.[1]
- The 3 types of apnea include central, obstructive, and mixed.
- Central sleep apnea (CSA) is characterized by a complete withdrawal of central respiratory drive to the inspiratory muscles, including the diaphragm, and results in the simultaneous absence of naso-oral airflow and thoracoabdominal excursions.
- In obstructive sleep apnea (OSA), the thoracic inspiratory muscles, including the diaphragm, are active, so thoracoabdominal excursions are seen.
- Absence of airflow results from upper-airway occlusion caused by lost pharyngeal dilator muscle tone, with consequent pharyngeal collapse.
- Obstructive sleep apnea is classified as mild (apnea-hypopnea index or AHI, 5–14), moderate (AHI, 15–30), or severe (AHI, >30)
- Mixed apnea has an initial central component followed by an obstructive component.
- Two types of hypopnea include obstructive or central.
For patient information about sleep apnea click here
For patient information about central sleep apnea click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D.
Clinical practice guidelines by the United States Preventive Services Task Force[1] and the American Academy of Sleep Medicine[2][3] address screening and diagnosis.
Diagnosis
Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Template:Diseases of the nervous system Template:SleepSeries2 Template:WH Template:WS
- ↑ US Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW et al. (2017) Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 317 (4):407-414. DOI:10.1001/jama.2016.20325 PMID: 28118461
- ↑ Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K; et al. (2017). “Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline”. J Clin Sleep Med. 13 (3): 479–504. doi:10.5664/jcsm.6506. PMC 5337595. PMID 28162150.
- ↑ Mokhlesi B, Cifu AS (2017). “Diagnostic Testing for Obstructive Sleep Apnea in Adults”. JAMA. 318 (20): 2035–2036. doi:10.1001/jama.2017.16722. PMID 29183053.
Pathophysiology
- Obstructive sleep apnea is characterized by recurrent pharyngeal collapse during sleep.
- Hypopnea or apnea occurs in the presence of pharynx collapse upon normal withdrawal of pharyngeal dilator muscle tone during sleep.
- Obesity and fat deposition around the pharynx are responsible of pharyngeal narrowing.
- During sleeping period, edema of the peripharyngeal area due to leg fluid redistribution, may predispose the patients to OSA.[2]
- Obstructive sleep apnea causes a drop in intrathoracic pressure, hypoxia, and arousal.[3]
- The drop in intrathoracic pressure increases left ventricular (LV) transmural pressure, and afterload.
- This drop in pressure increases venous return, causing right ventricular distention and a leftward shift of the interventricular septum and consequent decreased LV filling.
- Decreased LV filling and increased afterload lead to reduced stroke volume.
- Obstructive sleep apnea leading to elevations in systemic blood pressure (BP) secondary to hypoxia, arousals from sleep, and increased sympathetic nervous system activity (SNA).
- The combination of increased LV afterload and increased heart rate secondary to augmented SNA leads to myocardial oxygen supply/demand mismatch, cardiac ischemia and arrhythmias, LV hypertrophy, LV enlargement, and HF.
- Rapid-eye-movement (REM) sleep constitutes 20% to 25% of sleep and is associated with short surges of sympathetic activity.
- Sleep generally is a period of increased vagal activity and slower heart rates and lower BP. However, arousals after disordered breathing events in OSA leading to increase sympathetic nerve activity and risk of HF disease.
- Hypoxemia caused systolic and diastolic dysfunction may also lessen oxygen delivery to the myocardium.[4]
- Increased free oxygen radicals and inflammation may cause myocardial ischemia, arrhythmias, and sudden cardiac death.[5]
- Plasma nitrite concentrations, and endothelial-mediated vasodilation decrease in patients with OSA.
- Reactive oxygen species selectively activate inflammatory pathways.
- Activation of NFκB leads to increased production of tumor necrosis factor-α, interleukin-6, interleukin-8, and C-reactive protein, as well as adhesion molecules such as intracellular and vascular cell adhesion molecules, E selecting, and CD15, CD32.
- Activate inflammatory pathways can lead to endothelial damage, atherogenesis, and heart failure.
- Activate profibrotic transforming growth factor-β during inflammatory process leads to increased deposition of extracellular matrix and consequent myocardial fibrosis, and to worsening LV diastolic function.[6]
- Common risk factors of OSA in patients with HFrEF include older age, male sex, higher BMI, and habitual snoring.[7]
- In patients with HFrEF and HFpEF, OSA is more prevalent than in the general population.
- Predictors of risk OSA and CSA in HFrEF are atrial fibrillation, ventricular arrhythmias, lower LV ejection fraction (LVEF, and higher levels of serum brain natriuretic peptide (BNP), endothelin-1, and urinary norepinephrine.[7][8][9][8]
Pathophysiology is the study of the disturbance of normal mechanical, physical, and biochemical functions, either caused by a disease, or resulting from a disease or abnormal syndrome or condition that may not qualify to be called a disease.
An alternate definition is “the study of the biological and physical manifestations of disease as they correlate with the underlying abnormalities and physiological disturbances.”[1]
An example, from the field of infectious disease, would be the study of a toxin released by a bacterium, and what that toxin does to the body to cause harm, one possible result being sepsis. Another example is the study of the chemical changes that take place in body tissue due to inflammation.
Pathophysiology can be looked at as the intersection of two older, related disciplines: (normal) physiology and pathology.
Physiology is the study of normal, healthy bodily function (as opposed to anatomy, which is the study of normal structure). When something disrupts normal physiological processes, it enters the realm of pathophysiology.
Pathology, broadly speaking, is the “study of the nature and cause of disease.”[2] or the results of disease in the body. Pathophysiology looks at the detailed malfunctioning that comes from or, alternately, causes disease.
One caution in this approach is that healthy structure and function is not precisely the same in any two individuals.
Pathophysiology is a required study for under most nursing school programs in the United States as well as other countries.
See also
References
- Kumar, V., Abbas, A. and N. Fausto. 2004. Robbins & Cotran Pathologic Basis of Disease. Philadelphia: W. B. Saunders Company
Effect of CPAP in patients with HFrEF
- Use of nocturnal continuous positive airway pressure (CPAP) in OSA and HFrEF was associated with reduced central sympathetic vasoconstrictor outflow and improve vagal modulation of the heart by increasing high-frequency heart rate variability.[10][11]
- Other advantages of use of CPAP in HFrEF include reduction in apnea-hypopnea index, number of arousal per night, and daytime systolic blood pressure and heart rate combined with decrease in left ventricular end-systolic diameter and an 8.8% absolute increase in LVEF.[12][13]
- Use of CPAP was associated with improvement in quality of life.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Positive airway pressure (PAP) is a method of respiratory ventilation used primarily in the treatment of sleep apnea, for which it was first developed.
PAP ventilation is also commonly used for critically ill patients in hospital with respiratory failure, and in newborn infants (neonates). In these patients, PAP ventilation can prevent the need for endotracheal intubation, or allow earlier extubation.
Machine
A Continuous Positive Airway Pressure (CPAP) machine is used mainly by patients for the treatment of sleep apnea at home. Obstructive sleep apnea occurs when the upper airway becomes narrow as the muscles relax naturally during sleep. This reduces oxygen in the blood and causes arousal from sleep. The CPAP machine stops this phenomenon by delivering a stream of compressed air via a hose to a nasal pillow, nose mask or full-face mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas. This has the additional benefit of reducing or eliminating snoring.
The CPAP machine blows air at a prescribed pressure (also called the titrated pressure). The necessary pressure is usually determined by a sleep physician after review of a study supervised by a sleep technician during an overnight study (polysomnography) in a sleep laboratory. The titrated pressure is the pressure of air at which most (if not all) apneas and hypopneas have been prevented, and it is usually measured in centimetres of water (cm H2O). The pressure required by most patients with sleep apnea ranges between 6 and 14 cm H2O. A typical CPAP machine can deliver pressures between 4 and 20 cm H2O. More specialized units can deliver pressures up to 25 or 30 cm H2O.
CPAP treatment can be highly effective in treatment of obstructive sleep apnea. [1] For some patients, the improvement in the quality of sleep and quality of life due to CPAP treatment will be noticed after a single night’s use.
Prospective CPAP candidates are often reluctant to use this therapy, since the nose mask and hose to the machine look uncomfortable and clumsy, and the airflow required for some patients can be vigorous. Some patients adjust to the treatment within a few weeks, others struggle for longer periods, and some discontinue treatment entirely.
Therapy compliance on the part of the patient can be improved with support from a durable medical equipment (DME) provider, including allowing the patient his or her choice of PAP devices. PAP manufacturers frequently offer different models at different price ranges, and PAP masks have many different sizes and shapes, so that some users need to try several masks before finding a good fit.
History
Professor Colin Sullivan first developed the Continuous Positive Airway Pressure (CPAP) system at Royal Prince Alfred Hospital in 1981.
Types
- Fixed-pressure CPAP (Continuous Positive Airway Pressure) provides one constant pressure to the patient
- APAP or AutoPAP or AutoCPAP (Automatic Positive Airway Pressure) automatically titrates, or tunes, the amount of pressure delivered to the patient to the minimum required to maintain an unobstructed airway on a breath-by-breath basis by measuring the resistance in the patient’s breathing, thereby giving the patient the precise pressure required at a given moment and avoiding the compromise of fixed pressure.
- VPAP™ or BiPAP® (Variable/Bilevel Positive Airway Pressure) provides two levels of pressure: one for inhalation (IPAP) and a lower pressure during exhalation (EPAP)
- xPAP ST (Spontaneous Time) is a machine that forces a number of set breaths per minute and is used to treat patients with central apneas.
Components
- Flow generator (PAP machine) provides the compressed air
- Hose connects the flow generator (sometimes via a humidifer) to the inferface
- Interface (mask) provides the connection to the user’s airway
Optional features
- Humidifier adds moisture to the air
- Heated: Heated water chamber that can increase patient comfort by eliminating the dryness of the compressed air. The temperature can usually be adjusted or turned off to act as a passive humidifier if desired.
- Passive: Air is blown through an unheated water chamber and is dependent on ambient air temperature. It is not as effective as the heated humidifier described above, but still can increase patient comfort by eliminating the dryness of the compressed air.
- Ramp is used to temporarily lower the pressure to allow the user to fall asleep more easily. The pressure gradually rises to the prescribed level over a period of time that can be adjusted by the patient and/or the DME provider.
- Exhalation pressure relief: Gives a short drop in pressure during exhalation to reduce the effort required. This feature is known by the trade name C-Flex® in some PAPs made by Respironics and EPR™ in ResMed machines.
- Flexible chin straps are used to help the patient not breathe through the mouth, thereby keeping a closed pressure system. The straps are elastic enough that the patient can easily open his mouth if he feels that he needs to.
- Data logging records basic compliance info or detailed event logging, allowing the sleep physician (or patient) to download and analyze data recorded by the machine to verify treatment effectiveness.
Such features generally increase the likelihood of PAP tolerance and compliance. [2]
Care and maintenance
As with all durable medical equipment, proper maintenance is essential for proper functioning, long unit life and patient comfort. The care and maintenance required for PAP machines varies with the type and conditions of use, and are typically spelled out in a detailed instruction manual specific to the make and model.
Most manufacturers recommend that the end user perform weekly maintenance. Units must be checked regularly for wear and tear and kept clean. Worn or frayed electrical connections may present a shock or fire hazard; worn hoses and masks may reduce the effectiveness of the unit. Most units employ some type of filtration, and the filters must be cleaned or replaced on a regular schedule. Hoses and masks accumulate exfoliated skin, particulate matter, and can even develop mold. Humidification units must be kept free of mold and algae. Because units use substantial electrical power, housings must be cleaned without immersion.
Portability
Since continuous compliance is an important factor in the success of treatment, it is of importance that patients who travel have access to portable equipment. Progressively, nPAP units are becoming lighter and more compact, and often come with carrying cases. Dual-voltage power supplies permit many units to be used internationally.
Air travel presents special considerations. Most airport security inspectors have seen the portable machines, so screening rarely presents a special problem. Increasingly, machines are capable of being powered by the 400 Hz power supply used on most commercial aircraft and include manual or automatic altitude adjustment.
Some patients on PAP therapy also use supplementary oxygen. When provided in the form of bottled gas, this can present an increased risk of fire and is subject to restrictions. (Commercial airlines generally forbid passengers to bring their own oxygen.) As of November, 2006, most airlines permit the use of oxygen concentrators.
Availability
In many countries, PAP machines are only available by prescription. A sleep study at an accredited sleep lab is usually necessary before treatment can start. This is because the pressure settings on the PAP machine must be tailored to a patient’s treatment needs. A doctor, who may be a Respiratory Medicine, Ear Nose and Throat (ENT) or Neurology specialist, will interpret the results from the initial sleep study and estimate the correct pressure from experience. This is later confirmed with a follow up sleep study during which the patient wears the CPAP mask and pressure is adjusted up and down from the prescribed setting to find the optimal setting.
- In the United States, PAP machines are often available at large discounts online, but a patient purchasing a PAP personally must handle the responsibility of securing reimbursement from his or her insurance Medicaid. Many of the internet providers that deal with insurance such as Medicare will provide upgraded equipment to a patient even if he or she only qualifies for a basic PAP. In some locations a government program, separate from Medicare, can be used to claim a reimbursement for all or part of the cost of the PAP device.
- In the United Kingdom, PAP machines are available on National Health Service prescription after a diagnosis of sleep apnea or privately from the internet provided a prescription is supplied.
- In Australia, PAP machines can be bought from internet or physical stores, There is no requirement for a doctor’s prescription, however many suppliers will require a referral. Low-income earners who hold a Commonwealth Health Care Card should enquire with their state’s health department about programs that provide free or low-cost PAP machines. Those who have private health insurance may be eligible for a partial rebate on the cost of a CPAP machine and the mask. Superannuation may be released for the purchase of essential medical equipment such as PAP machines, on the provision of letters from two doctors, one of whom must be your specialist, and an application to the Australian Prudential Regulation Authority (APRA).
In a hospital setting
PAP ventilation is often used for patients who have acute type 1 or 2 respiratory failure. Usually PAP ventilation will be reserved for the subset of patients for whom oxygen delivered via a face mask is deemed to be insufficient or deleterious to health (see CO₂ retention). Usually, patients on PAP ventilation will be closely monitored in an intensive care, high dependency, coronary care unit or specialist respiratory unit.
The most common conditions for which PAP ventilation is used in hospital are congestive cardiac failure and acute exacerbation of obstructive airways disease, most notably exacerbations of COPD and asthma. It is not used in cases where the airway may be compromised, or consciousness is impaired.
The mask required to deliver CPAP must have a tight seal, and be held on very firmly. Most people find wearing the mask uncomfortable. Breathing out against the positive pressure resistance (the expiratory positive airway pressure component, or EPAP) is also unpleasant. These factors lead to inability to continue treatment due to patient intolerance in about 20% of cases where it is initiated. Obviously those who suffer an anxiety disorder or claustrophobia are more likely to be unable to tolerate PAP treatment. Sometimes medication will be given to assist with the anxiety caused by PAP ventilation.
Unlike PAP used at home to splint the tongue and pharynx, PAP is used in hospital to improve the ability of the lung to exchange oxygen and carbon dioxide, and to decrease the work of breathing (the energy expended moving air into and out of the alveoli). This is because:
- During inspiration, the inspiratory positive airway pressure, or IPAP, forces air into the lungs – thus less work is required from the respiratory muscles.
- The bronchioles and alveoli are prevented from collapsing at the end of expiration. If these small airways and alveoli are allowed to collapse, significant pressures are required to re-expand them. This is because of the Young-Laplace equation (which explains why the hardest part of blowing up a balloon is the first breath).
- Entire regions of the lung that would otherwise be collapsed are forced and held open. This process is called recruitment. Usually these collapsed regions of lung will have some blood flow (although reduced). Because these areas of lung are not being ventilated the blood passing through these areas is not able to efficiently exchange oxygen and carbon dioxide. This is called ventilation/perfusion (or V/Q) mismatch. The recruitment reduces ventilation perfusion mismatch.
- The amount of air remaining in the lungs at the end of a breath is greater (this is called the Functional residual capacity). The chest and lungs are therefore more expanded. From this more expanded resting position, less work is required to inspire. This is due to the non-linear compliance-volume curve of the lung.
References
- ↑ Montserrat, Josep (August 2001). “Effectiveness of CPAP Treatment in Daytime Function in Sleep Apnea Syndrome”. American Journal of Respiratory and Critical Care Medicine. 164 (4): 608–618. Unknown parameter
|coauthors=ignored (help) - ↑ Richards, Dianne (May 2007). “Increased Adherence to CPAP With a Group Cognitive Behavioral Treatment Intervention: A Randomized Trial”. Journal SLEEP. 30 (05): 635–640. Unknown parameter
|coauthors=ignored (help)
Effect of CPAP in patients with HFpEF
- There are no clinical trials regarding the effects of chronic CPAP therapy in patients with OSA and HFpEF. However, CPAP therapy may have beneficial effects on diastolic function as follows:
- Decreased diastolic blood pressure
- Improved systolic and diastolic function (increased E/A ratio, decreased IVRT)[14]
- Regression of LV hypertrophy[14]
- Reduced LV wall thickness (interventricular septum and LV posterior wall)[15]
- Improved diastolic velocities
- Mortality rate was not decreased after use of CPAP in heart failure patients (HFpEF, HFrEF) with OSA.[16]

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Positive airway pressure (PAP) is a method of respiratory ventilation used primarily in the treatment of sleep apnea, for which it was first developed.
PAP ventilation is also commonly used for critically ill patients in hospital with respiratory failure, and in newborn infants (neonates). In these patients, PAP ventilation can prevent the need for endotracheal intubation, or allow earlier extubation.
Machine
A Continuous Positive Airway Pressure (CPAP) machine is used mainly by patients for the treatment of sleep apnea at home. Obstructive sleep apnea occurs when the upper airway becomes narrow as the muscles relax naturally during sleep. This reduces oxygen in the blood and causes arousal from sleep. The CPAP machine stops this phenomenon by delivering a stream of compressed air via a hose to a nasal pillow, nose mask or full-face mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas. This has the additional benefit of reducing or eliminating snoring.
The CPAP machine blows air at a prescribed pressure (also called the titrated pressure). The necessary pressure is usually determined by a sleep physician after review of a study supervised by a sleep technician during an overnight study (polysomnography) in a sleep laboratory. The titrated pressure is the pressure of air at which most (if not all) apneas and hypopneas have been prevented, and it is usually measured in centimetres of water (cm H2O). The pressure required by most patients with sleep apnea ranges between 6 and 14 cm H2O. A typical CPAP machine can deliver pressures between 4 and 20 cm H2O. More specialized units can deliver pressures up to 25 or 30 cm H2O.
CPAP treatment can be highly effective in treatment of obstructive sleep apnea. [1] For some patients, the improvement in the quality of sleep and quality of life due to CPAP treatment will be noticed after a single night’s use.
Prospective CPAP candidates are often reluctant to use this therapy, since the nose mask and hose to the machine look uncomfortable and clumsy, and the airflow required for some patients can be vigorous. Some patients adjust to the treatment within a few weeks, others struggle for longer periods, and some discontinue treatment entirely.
Therapy compliance on the part of the patient can be improved with support from a durable medical equipment (DME) provider, including allowing the patient his or her choice of PAP devices. PAP manufacturers frequently offer different models at different price ranges, and PAP masks have many different sizes and shapes, so that some users need to try several masks before finding a good fit.
History
Professor Colin Sullivan first developed the Continuous Positive Airway Pressure (CPAP) system at Royal Prince Alfred Hospital in 1981.
Types
- Fixed-pressure CPAP (Continuous Positive Airway Pressure) provides one constant pressure to the patient
- APAP or AutoPAP or AutoCPAP (Automatic Positive Airway Pressure) automatically titrates, or tunes, the amount of pressure delivered to the patient to the minimum required to maintain an unobstructed airway on a breath-by-breath basis by measuring the resistance in the patient’s breathing, thereby giving the patient the precise pressure required at a given moment and avoiding the compromise of fixed pressure.
- VPAP™ or BiPAP® (Variable/Bilevel Positive Airway Pressure) provides two levels of pressure: one for inhalation (IPAP) and a lower pressure during exhalation (EPAP)
- xPAP ST (Spontaneous Time) is a machine that forces a number of set breaths per minute and is used to treat patients with central apneas.
Components
- Flow generator (PAP machine) provides the compressed air
- Hose connects the flow generator (sometimes via a humidifer) to the inferface
- Interface (mask) provides the connection to the user’s airway
Optional features
- Humidifier adds moisture to the air
- Heated: Heated water chamber that can increase patient comfort by eliminating the dryness of the compressed air. The temperature can usually be adjusted or turned off to act as a passive humidifier if desired.
- Passive: Air is blown through an unheated water chamber and is dependent on ambient air temperature. It is not as effective as the heated humidifier described above, but still can increase patient comfort by eliminating the dryness of the compressed air.
- Ramp is used to temporarily lower the pressure to allow the user to fall asleep more easily. The pressure gradually rises to the prescribed level over a period of time that can be adjusted by the patient and/or the DME provider.
- Exhalation pressure relief: Gives a short drop in pressure during exhalation to reduce the effort required. This feature is known by the trade name C-Flex® in some PAPs made by Respironics and EPR™ in ResMed machines.
- Flexible chin straps are used to help the patient not breathe through the mouth, thereby keeping a closed pressure system. The straps are elastic enough that the patient can easily open his mouth if he feels that he needs to.
- Data logging records basic compliance info or detailed event logging, allowing the sleep physician (or patient) to download and analyze data recorded by the machine to verify treatment effectiveness.
Such features generally increase the likelihood of PAP tolerance and compliance. [2]
Care and maintenance
As with all durable medical equipment, proper maintenance is essential for proper functioning, long unit life and patient comfort. The care and maintenance required for PAP machines varies with the type and conditions of use, and are typically spelled out in a detailed instruction manual specific to the make and model.
Most manufacturers recommend that the end user perform weekly maintenance. Units must be checked regularly for wear and tear and kept clean. Worn or frayed electrical connections may present a shock or fire hazard; worn hoses and masks may reduce the effectiveness of the unit. Most units employ some type of filtration, and the filters must be cleaned or replaced on a regular schedule. Hoses and masks accumulate exfoliated skin, particulate matter, and can even develop mold. Humidification units must be kept free of mold and algae. Because units use substantial electrical power, housings must be cleaned without immersion.
Portability
Since continuous compliance is an important factor in the success of treatment, it is of importance that patients who travel have access to portable equipment. Progressively, nPAP units are becoming lighter and more compact, and often come with carrying cases. Dual-voltage power supplies permit many units to be used internationally.
Air travel presents special considerations. Most airport security inspectors have seen the portable machines, so screening rarely presents a special problem. Increasingly, machines are capable of being powered by the 400 Hz power supply used on most commercial aircraft and include manual or automatic altitude adjustment.
Some patients on PAP therapy also use supplementary oxygen. When provided in the form of bottled gas, this can present an increased risk of fire and is subject to restrictions. (Commercial airlines generally forbid passengers to bring their own oxygen.) As of November, 2006, most airlines permit the use of oxygen concentrators.
Availability
In many countries, PAP machines are only available by prescription. A sleep study at an accredited sleep lab is usually necessary before treatment can start. This is because the pressure settings on the PAP machine must be tailored to a patient’s treatment needs. A doctor, who may be a Respiratory Medicine, Ear Nose and Throat (ENT) or Neurology specialist, will interpret the results from the initial sleep study and estimate the correct pressure from experience. This is later confirmed with a follow up sleep study during which the patient wears the CPAP mask and pressure is adjusted up and down from the prescribed setting to find the optimal setting.
- In the United States, PAP machines are often available at large discounts online, but a patient purchasing a PAP personally must handle the responsibility of securing reimbursement from his or her insurance Medicaid. Many of the internet providers that deal with insurance such as Medicare will provide upgraded equipment to a patient even if he or she only qualifies for a basic PAP. In some locations a government program, separate from Medicare, can be used to claim a reimbursement for all or part of the cost of the PAP device.
- In the United Kingdom, PAP machines are available on National Health Service prescription after a diagnosis of sleep apnea or privately from the internet provided a prescription is supplied.
- In Australia, PAP machines can be bought from internet or physical stores, There is no requirement for a doctor’s prescription, however many suppliers will require a referral. Low-income earners who hold a Commonwealth Health Care Card should enquire with their state’s health department about programs that provide free or low-cost PAP machines. Those who have private health insurance may be eligible for a partial rebate on the cost of a CPAP machine and the mask. Superannuation may be released for the purchase of essential medical equipment such as PAP machines, on the provision of letters from two doctors, one of whom must be your specialist, and an application to the Australian Prudential Regulation Authority (APRA).
In a hospital setting
PAP ventilation is often used for patients who have acute type 1 or 2 respiratory failure. Usually PAP ventilation will be reserved for the subset of patients for whom oxygen delivered via a face mask is deemed to be insufficient or deleterious to health (see CO₂ retention). Usually, patients on PAP ventilation will be closely monitored in an intensive care, high dependency, coronary care unit or specialist respiratory unit.
The most common conditions for which PAP ventilation is used in hospital are congestive cardiac failure and acute exacerbation of obstructive airways disease, most notably exacerbations of COPD and asthma. It is not used in cases where the airway may be compromised, or consciousness is impaired.
The mask required to deliver CPAP must have a tight seal, and be held on very firmly. Most people find wearing the mask uncomfortable. Breathing out against the positive pressure resistance (the expiratory positive airway pressure component, or EPAP) is also unpleasant. These factors lead to inability to continue treatment due to patient intolerance in about 20% of cases where it is initiated. Obviously those who suffer an anxiety disorder or claustrophobia are more likely to be unable to tolerate PAP treatment. Sometimes medication will be given to assist with the anxiety caused by PAP ventilation.
Unlike PAP used at home to splint the tongue and pharynx, PAP is used in hospital to improve the ability of the lung to exchange oxygen and carbon dioxide, and to decrease the work of breathing (the energy expended moving air into and out of the alveoli). This is because:
- During inspiration, the inspiratory positive airway pressure, or IPAP, forces air into the lungs – thus less work is required from the respiratory muscles.
- The bronchioles and alveoli are prevented from collapsing at the end of expiration. If these small airways and alveoli are allowed to collapse, significant pressures are required to re-expand them. This is because of the Young-Laplace equation (which explains why the hardest part of blowing up a balloon is the first breath).
- Entire regions of the lung that would otherwise be collapsed are forced and held open. This process is called recruitment. Usually these collapsed regions of lung will have some blood flow (although reduced). Because these areas of lung are not being ventilated the blood passing through these areas is not able to efficiently exchange oxygen and carbon dioxide. This is called ventilation/perfusion (or V/Q) mismatch. The recruitment reduces ventilation perfusion mismatch.
- The amount of air remaining in the lungs at the end of a breath is greater (this is called the Functional residual capacity). The chest and lungs are therefore more expanded. From this more expanded resting position, less work is required to inspire. This is due to the non-linear compliance-volume curve of the lung.
References
- ↑ Montserrat, Josep (August 2001). “Effectiveness of CPAP Treatment in Daytime Function in Sleep Apnea Syndrome”. American Journal of Respiratory and Critical Care Medicine. 164 (4): 608–618. Unknown parameter
|coauthors=ignored (help) - ↑ Richards, Dianne (May 2007). “Increased Adherence to CPAP With a Group Cognitive Behavioral Treatment Intervention: A Randomized Trial”. Journal SLEEP. 30 (05): 635–640. Unknown parameter
|coauthors=ignored (help)
2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) [17]
2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) [17]
Management of Sleep Disorders
| Class IIa |
| “1. In patients with HF and suspicion of sleep-disordered breathing, a formal sleep assessment is reasonable to confirm the diagnosis and differentiate between obstructive and central sleep apnea. [18][19](Level of Evidence: C-LD) ” |
| “2. In patients with HF and obstructive sleeep apnea, continuous positive airway pressure may be reasonable to improve sleep quality and decrease daytime sleepiness. [18][20][21][22](Level of Evidence: B-R) ” |
| Class III (Harm) |
| “3. In patients with NYHA class II to IV HFrEF and central sleep apnea, adaptive servo-ventilation causes harm. [20][21] (Level of Evidence: B-R) ” |
Source
Source
References
References
- ↑ Chowdhury M, Adams S, Whellan DJ (February 2010). “Sleep-disordered breathing and heart failure: focus on obstructive sleep apnea and treatment with continuous positive airway pressure”. J Card Fail. 16 (2): 164–74. doi:10.1016/j.cardfail.2009.08.006. PMID 20142029.
- ↑ Remmers JE, deGroot WJ, Sauerland EK, Anch AM (June 1978). “Pathogenesis of upper airway occlusion during sleep”. J Appl Physiol Respir Environ Exerc Physiol. 44 (6): 931–8. doi:10.1152/jappl.1978.44.6.931. PMID 670014.
- ↑ Brinker JA, Weiss JL, Lappé DL, Rabson JL, Summer WR, Permutt S, Weisfeldt ML (March 1980). “Leftward septal displacement during right ventricular loading in man”. Circulation. 61 (3): 626–33. doi:10.1161/01.cir.61.3.626. PMID 7353253.
- ↑ Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL (March 1999). “Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha”. J Clin Invest. 103 (5): 691–6. doi:10.1172/JCI5912. PMC 408131. PMID 10074486.
- ↑ Wyman RM, Farhi ER, Bing OH, Johnson RG, Weintraub RM, Grossman W (January 1989). “Comparative effects of hypoxia and ischemia in the isolated, blood-perfused dog heart: evaluation of left ventricular diastolic chamber distensibility and wall thickness”. Circ Res. 64 (1): 121–8. doi:10.1161/01.res.64.1.121. PMID 2909295.
- ↑ Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschöpe C (January 2011). “Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction”. Circ Heart Fail. 4 (1): 44–52. doi:10.1161/CIRCHEARTFAILURE.109.931451. PMID 21075869.
- ↑ 7.0 7.1 Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD (May 2009). “Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction”. J Card Fail. 15 (4): 279–85. doi:10.1016/j.cardfail.2008.11.015. PMID 19398074.
- ↑ 8.0 8.1 Vazir A, Hastings PC, Dayer M, McIntyre HF, Henein MY, Poole-Wilson PA, Cowie MR, Morrell MJ, Simonds AK (March 2007). “A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction”. Eur J Heart Fail. 9 (3): 243–50. doi:10.1016/j.ejheart.2006.08.001. PMID 17030014.
- ↑ Javaheri S (January 2006). “Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report”. Int J Cardiol. 106 (1): 21–8. doi:10.1016/j.ijcard.2004.12.068. PMID 16321661.
- ↑ Usui K, Bradley TD, Spaak J, Ryan CM, Kubo T, Kaneko Y, Floras JS (June 2005). “Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure”. J Am Coll Cardiol. 45 (12): 2008–11. doi:10.1016/j.jacc.2004.12.080. PMID 15963401.
- ↑ Gilman MP, Floras JS, Usui K, Kaneko Y, Leung RS, Bradley TD (February 2008). “Continuous positive airway pressure increases heart rate variability in heart failure patients with obstructive sleep apnoea”. Clin Sci (Lond). 114 (3): 243–9. doi:10.1042/CS20070172. PMID 17824846.
- ↑ Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD (March 2003). “Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea”. N Engl J Med. 348 (13): 1233–41. doi:10.1056/NEJMoa022479. PMID 12660387.
- ↑ Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT (February 2004). “Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure”. Am J Respir Crit Care Med. 169 (3): 361–6. doi:10.1164/rccm.200306-752OC. PMID 14597482.
- ↑ 14.0 14.1 Cloward TV, Walker JM, Farney RJ, Anderson JL (August 2003). “Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure”. Chest. 124 (2): 594–601. doi:10.1378/chest.124.2.594. PMID 12907548.
- ↑ Akar Bayram N, Ciftci B, Durmaz T, Keles T, Yeter E, Akcay M, Bozkurt E (May 2009). “Effects of continuous positive airway pressure therapy on left ventricular function assessed by tissue Doppler imaging in patients with obstructive sleep apnoea syndrome”. Eur J Echocardiogr. 10 (3): 376–82. doi:10.1093/ejechocard/jen257. PMID 18845553.
- ↑ Jilek C, Krenn M, Sebah D, Obermeier R, Braune A, Kehl V, Schroll S, Montalvan S, Riegger GA, Pfeifer M, Arzt M (January 2011). “Prognostic impact of sleep disordered breathing and its treatment in heart failure: an observational study”. Eur J Heart Fail. 13 (1): 68–75. doi:10.1093/eurjhf/hfq183. PMID 20961913.
- ↑ Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM; et al. (2022). “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines”. Circulation. 145 (18): e876–e894. doi:10.1161/CIR.0000000000001062. PMID 35363500 Check
|pmid=value (help). - ↑ 18.0 18.1 Arzt M, Schroll S, Series F, Lewis K, Benjamin A, Escourrou P; et al. (2013). “Auto-servoventilation in heart failure with sleep apnoea: a randomised controlled trial”. Eur Respir J. 42 (5): 1244–54. doi:10.1183/09031936.00083312. PMID 23222879.
- ↑ Arzt M, Floras JS, Logan AG, Kimoff RJ, Series F, Morrison D; et al. (2007). “Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP)”. Circulation. 115 (25): 3173–80. doi:10.1161/CIRCULATIONAHA.106.683482. PMID 17562959.
- ↑ 20.0 20.1 O’Connor CM, Whellan DJ, Fiuzat M, Punjabi NM, Tasissa G, Anstrom KJ; et al. (2017). “Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial”. J Am Coll Cardiol. 69 (12): 1577–1587. doi:10.1016/j.jacc.2017.01.041. PMID 28335841.
- ↑ 21.0 21.1 Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E; et al. (2015). “Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure”. N Engl J Med. 373 (12): 1095–105. doi:10.1056/NEJMoa1506459. PMC 4779593. PMID 26323938.
- ↑ Yamamoto S, Yamaga T, Nishie K, Nagata C, Mori R (2019). “Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure”. Cochrane Database Syst Rev. 12: CD012803. doi:10.1002/14651858.CD012803.pub2. PMC 6891032 Check
|pmc=value (help). PMID 31797360. - ↑ Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (May 2022). “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines”. Circulation. 145 (18): e895–e1032. doi:10.1161/CIR.0000000000001063. PMID 35363499 Check
|pmid=value (help).
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
